06.12.2018 • NewsAGCBoehringer IngelheimElaine Burridge

Japan’s AGC to buy Malgrat Pharma

Japan’s AGC to buy Malgrat Pharma (c) AGC
Japan’s AGC to buy Malgrat Pharma (c) AGC

Japan’s AGC, formerly Asahi Glass Co., has agreed to buy Malgrat Pharma Chemicals (MPC), a Spanish subsidiary of Boehringer Ingelheim that manufactures synthetic pharmaceutical active ingredients for the German group. Financial terms were not disclosed.

The acquisition will give AGC a foothold in Europe and broaden its presence as a contract development and manufacturing organization (CDMO) for the European pharmaceutical industry.

MPC makes cGMP-compliant commercialized synthetic pharmaceuticals for Boehringer as well as compounds in clinical development on a range of scales.

Combining MPC’s capabilities and assets with its own, AGC said it will leverage its own fluorination technologies and extensive in-house experience in drug discovery along with the CDMO business it has built up in Japan.

The deal also gives AGC its first site in Europe that is registered with the US Food and Drug Administration (FDA).

The Tokyo-headquartered group has identified life sciences as one of its strategic businesses. AGC said it will continue to actively invest in this sector to provide globally unified high-quality services to the synthetic drug and biopharmaceutical industries.

 

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.